Bessar Hagar, Venditti Iole, Benassi Luisa, Vaschieri Cristina, Azzoni Paola, Pellacani Giovanni, Magnoni Cristina, Botti Elisabetta, Casagrande Viviana, Federici Massimo, Costanzo Antonio, Fontana Laura, Testa Giovanna, Mostafa Fawzia Farag, Ibrahim Samia Ali, Russo Maria Vittoria, Fratoddi Ilaria
Dermatology Department, Faculty of Medicine, Zagazig University, 44519, Sharkia, Egypt.
Department of Chemistry, University Sapienza of Rome, p.le Aldo Moro 5, 00185 Rome, Italy.
Colloids Surf B Biointerfaces. 2016 May 1;141:141-147. doi: 10.1016/j.colsurfb.2016.01.021. Epub 2016 Jan 16.
Gold nanoparticles (AuNPs) represent an effective choice for topical drug delivery systems thanks to their small size, general non-toxicity, ease of functionalization and high surface to volume ratio. Even if systemic, methotrexate still plays an important role in psoriasis treatment: its topical use shows insufficient percutaneus penetration owing to limited passive diffusion, high molecular weight and dissociation at physiological pH. The aim of our study was to design a new drug delivery nanocarrier for Methotrexate and to improve its solubility, stability and biodistribution. AuNPs were on purpose prepared with a hydrophilic stabilizing layer, in order to improve the colloidal stability in water. Water-soluble gold nanoparticles functionalized by sodium 3-mercapto-1-propansulfonate (Au-3MPS) were prepared and loaded with methotrexate (MTX). The loading efficiency of MTX on Au-3MPS was assessed in the range 70-80%, with a fast release (80% in one hour). The release was studied up to 24h reaching the value of 95%. The Au-3MPS@MTX conjugate was fully characterized by spectroscopic techniques (UV-vis, FTIR) and DLS. Preliminary toxicity tests in the presence of keratinocytes monolayers allowed to assess that the used Au-3MPS are not toxic. The conjugate was then topically used on C57BL/6 mouse normal skin in order to trace the absorption behavior. STEM images clearly revealed the distribution of gold nanoparticles inside the cells. In vitro studies showed that Methotrexate conjugated with Au-3MPS is much more efficient than Methotrexate alone. Moreover, DL50, based on MTT analysis, is 20 folds reduced at 48 h, by the presence of nanoparticles conjugation. UV-vis spectra for in vivo tracing of the conjugate on bare mouse skin after 24h of application, show increased delivery of Methotrexate in the epidermis and dermis using Au-3MPS@MTX conjugate, compared to MTX alone. Moreover we observed absence of the Au-3MPS in the dermis and in the epidermis, suggesting that these layers of the skin do not retain the nanoparticles. Based on our data, we found that the novel Au-3MPS@MTX conjugate is an effective non-toxic carrier for the satisfactory percutaneous absorption of Methotrexate and could help in possible topical treatment of psoriasis.
由于金纳米颗粒(AuNPs)尺寸小、一般无毒、易于功能化且表面积与体积比高,它们是局部给药系统的有效选择。即使是全身用药,甲氨蝶呤在银屑病治疗中仍发挥着重要作用:由于被动扩散有限、分子量高以及在生理pH值下会解离,其局部使用时经皮渗透不足。我们研究的目的是设计一种用于甲氨蝶呤的新型药物递送纳米载体,并改善其溶解性、稳定性和生物分布。特意制备了具有亲水性稳定层的AuNPs,以提高其在水中的胶体稳定性。制备了用3-巯基-1-丙烷磺酸钠功能化的水溶性金纳米颗粒(Au-3MPS)并负载甲氨蝶呤(MTX)。MTX在Au-3MPS上的负载效率在70 - 80%范围内,具有快速释放特性(1小时内释放80%)。研究了长达24小时的释放情况,释放量达到95%。通过光谱技术(紫外可见光谱、傅里叶变换红外光谱)和动态光散射对Au-3MPS@MTX共轭物进行了全面表征。在角质形成细胞单层存在的情况下进行的初步毒性测试表明所使用的Au-3MPS无毒。然后将该共轭物局部应用于C57BL/6小鼠正常皮肤以追踪其吸收行为。扫描透射电子显微镜图像清楚地显示了金纳米颗粒在细胞内的分布。体外研究表明,与Au-3MPS共轭的甲氨蝶呤比单独的甲氨蝶呤效率高得多。此外,基于MTT分析,在存在纳米颗粒共轭的情况下,48小时时的半数致死剂量降低了20倍。应用24小时后,在裸鼠皮肤上对该共轭物进行体内追踪的紫外可见光谱显示,与单独使用MTX相比,使用Au-3MPS@MTX共轭物时甲氨蝶呤在表皮和真皮中的递送增加。此外,我们观察到真皮和表皮中不存在Au-3MPS,这表明皮肤的这些层不会保留纳米颗粒。根据我们的数据,我们发现新型Au-3MPS@MTX共轭物是一种有效的无毒载体,可实现甲氨蝶呤令人满意的经皮吸收,并有助于银屑病的可能局部治疗。